Introduction
============

The cause of peripheral facial nerve palsy (FNP) or Bell\'s palsy, as well as that of sudden deafness (SD), is often unknown. In Sweden, between 0.1 and 0.3 per 1000 of the population are diagnosed every year with one of these disorders. It is known that palsies can be associated with reactivated herpes simplex virus or a specific immune response to infection. Other possible explanations are varicella zoster virus or Lyme borreliosis (LB), especially in children or in bilateral palsy, or sometimes sarcoidosis. Sudden deafness, on the other hand, is thought to be due to a viral and/or bacterial infection, trauma, neoplasms, otologic disease, or vascular or haematological disorders. The majority of the cases remain idiopathic [@b1],[@b2].

Rickettsioses have not been implicated as causative agents but, based on serological evidence, have occasionally been associated with these diseases [@b3],[@b4]. Rickettsioses are systemic diseases with symptoms caused by vasculitis, which results from proliferation of rickettsiae in vascular endothelial cells. Of the spotted fever rickettsiae (SFR), neurological manifestations occur in some cases; meningitis or involvement of the peripheral nervous system has typically been reported in cases presenting severe systemic manifestations [@b4]--[@b6]. *Rickettsia felis*, an SFR, is reported to have worldwide distribution, with cat fleas (*Ctenophalides felis*) being the main reservoir and vector in disease transmission to humans. Its pathogenic role in humans has been demonstrated through PCR and serology in about 70 cases, and the typical symptoms are characterized by fever, headache, myalgia, cutaneous manifestations (rash, eschar), lymphadenopathy and neurological manifestations (photophobia, hearing loss) [@b7]--[@b9]. *Rickettsia helvetica* is the only reported tick-transmitted SFR in Sweden (besides a single reported finding of *Rickettsia sibirica)*, occurring in approximately 9%--10% of *Ixodes ricinus* ticks [@b10]. A handful of infected patients have presented with a febrile illness similar to *R. felis*, occasionally myocarditis but in two cases meningitis, where the organism was also isolated from cerebrospinal fluid (CSF), including one patient with concomitant reactivation of herpes virus 2 [@b11]--[@b13]. In an ongoing investigation of patients with different neurological manifestations, two cases with subacute meningitis caused by *R. felis* were also found recently [@b14]. However, thus far *R. felis* has not been reported in any vector in Sweden.

Here one retrospective and one prospective study of a total of 127 patients diagnosed at the Otorhinolaryngology Clinic, Falun Hospital, Sweden, and Uppsala University Hospital, Uppsala, Sweden, and presenting symptoms associated with the seventh and eighth cranial nerves are reported as well as serological and molecular evidence of *Rickettsia* spp. infection.

Material and methods
====================

Patients, serum and cerebrospinal fluid
---------------------------------------

### Retrospective study (Study 1)

Samples of serum from 40 patients diagnosed with FNP and 30 patients presenting with SD, previously stored at −20°C in a regular freezer, were thawed and re-examined for the presence of rickettsial antibodies. Five of the patients with FNP and one with SD had undergone lumbar puncture and were examined for *Rickettsia* spp. using PCR. Cerebrospinal fluid samples were taken at the same time as the serum samples. The samples had been collected from 2009 to 2011 and diagnoses had previously been made at the Otorhinolaryngology Clinic, Falun Hospital, and in some cases at Uppsala University Hospital. The patients were between 6 and 84 years of age (34 female and 36 male). Most patients had sought medical care within 1 week after symptom onset, with a range up to 3 months, and were sampled for serum at the time of the first doctor visit. In cases where one or more convalescent serum samples had been collected, they were examined in the same manner. The vast majority of patients had been treated with prednisolone or local treatment (drops, ointment, taping or humidity chamber), whilst a smaller number had received treatment with antiviral or antibacterial drugs.

### Prospective study (Study 2)

A total of 57 patients, of whom 20 showed FNP and 37 had sudden hearing loss, at the Otorhinolaryngology Clinic, Falun Hospital, were sampled for two sera (S1 and S2): sample 1 (S1) on enrolment day at the time of the first doctor visit and sample 2 (S2) collected 6--8 and up to 24 weeks later. All patients with FNP had severe dysfunction corresponding to grade V or VI according to the House−Brackman facial nerve grading system. SD was defined as sensorineural hearing loss over three contiguous pure-tone frequencies of 30 dB or more with a duration of less than 72 h. All sera were examined for the presence of rickettsial antibodies, in the same manner as in Study 1. The age distribution was between 23 and 74 years (27 female and 29 male patients). The distribution of symptom durations and applied treatments was similar to that in Study 1. PCR on the CSF of these patients was not performed because it is not usually part of the normal investigation and ethical permission had not been authorized for expanded diagnostics. In both Study 1 and Study 2, data on tick bite, symptoms, laboratory findings and initial treatment were obtained from the medical records (after informed consent) based on the initial examination and subsequent follow-up. Prior to or concurrent with our study, sera were analysed for antibodies against *Borrelia* spp.; in Study 2, paired sera were used.

Statistical analysis
--------------------

For continuous variables, standard parametric statistics (confidence interval according to Fleiss with Yates\'s correction) giving the mean* ± *95% confidence interval (CI) were used. Statistical analyses were conducted using Predictive Analytics Software (PASW®) Statistics version 20 (IBM, Portsmouth, NH, USA).

DNA extraction
--------------

Bacterial DNA was extracted from CSF using the NucliSens easyMAG automated extraction platform (bio-Mérieux, Durham, NC, USA), according to the manufacturer\'s instructions.

PCR
---

Direct cycle sequencing analysis of both strands of amplicons was performed using an automatic Hitachi 3100 Avant Plus Genetic Analyzer (Applied Biosystems, Tokyo, Japan). For species identification, pairwise similarities to and differences from other rickettsiae in the spotted fever group were examined using BLAST analysis. Multiple sequence alignments were conducted using BioEdit version 7.0.9 and ClustalW.

Serology
--------

For microimmunofluorescence, *R. helvetica*-infected Vero cells supplemented with 10% yolk sac solution were applied as the bacterial antigen to each well of the microscope slides, and then dried, fixed in acetone and incubated with serial dilutions of serum, as previously described [@b22]. As positive controls, a serum sample from a patient with a proven end-point IgG/IgM of 1:512/1:128 to *R. helvetica* was used. A human blood donor serum was used as a negative control. IgG and IgM antibodies were detected by fluorescein-isothiocyanate-conjugated γ- and μ-chain-specific polyclonal rabbit anti-human IgG and IgM (ref. F0202 and F0203, Dako, Glostrup, Denmark). Before examination of IgM, the serum was pretreated with rheumatoid factor absorbent (Immunkemi, Stockholm, Sweden). Titres \< 1:64 were considered negative for IgG/IgM. As per Centers for Disease Control and Prevention (Atlanta, GA, USA), a confirmed case was defined as a fourfold or greater rise in IgG titre between acute phase (S1) and convalescent phase (S2) sera taken at the onset and 4--6 weeks later and tested in parallel. Single IgG end-point titres of ≥1:256 were considered presumptive evidence of recent or current infection and defined as a probable case. Single IgG and/or IgM end-point titres ≥1:64 and \<1:256 were regarded as supportive evidence indicative of either past infection or early response to infection whilst persisting positive IgG titres with or without IgM reactivity were considered as past infection. Persisting IgM antibodies alone were interpreted as non-specific cross-reactivity due to exposure to other organisms or autoimmune responses or possibly a sign of a previous exposure. Laboratory evidence of a clinical or subclinical infection with *Borrelia burgdorferi* was based on comparison of acute and, in cases where applicable, convalescent sera, using a commercial enzyme-linked immunosorbent assay (ELISA), according to the manufacturer′s instructions \[Euroimmun AG (Aktiengesellschaft), Lübeck, Germany\], or the Lyme Borreliosis ELISA kit (Oxoid Ltd, Basingstoke, Hampshire, UK).

Western blot
------------

Sera from four of the IgG-positive patients (P12, P23, P29 and P44 in Table[2](#tbl2){ref-type="table"}) in Study 2 were diluted to 1:500 and tested for western blot (WB) with *R. helvetica* whole-cell antigen as previously described [@b23]. As the positive control a serum from rabbit immunized with purified *R. helvetica* was used, and the secondary antibody alone served as the negative control.

Absorption study
----------------

One of the samples (P23) with a titre ≥512 was selected for absorption. A minor aliquot of the undiluted serum sample was mixed in an equal volume with a concentrated Vero cell derived whole-cell *R. helvetica* antigen suspension, and then diluted in phosphate-buffered saline to a dilution of 1:600, incubated during gentle shaking for 5.5 h at 37°C, and then stored overnight at 5°C and centrifuged for 5 min at 20 000 *g* before serial twofold dilutions were made (1:600, 1:1200 and 1:2400) and used for WB [@b24]. The end-points of both absorbed and unabsorbed dilutions were compared also in immunofluorescence assay (IFA).

Results
=======

Study 1 (retrospective)
-----------------------

Of the 40 patients with facial palsy and 30 with SD, three (R11, R18 and R21) showed a fourfold rise in IgG titre judged as confirmative of infection (Table[1](#tbl1){ref-type="table"}). Correspondingly, three patients (R15, R25, R27) had serological findings with IgG titres ≥256 indicating a recent or current infection and judged as probable cases. One patient with SD (R33) showed a single IgG and IgM titre of 128 suggestive of infection. Sixteen of 40 and 10/30 patients, respectively, were seronegative, and 21/40 and 16/30, respectively, were sero-reactive with titres between ≥64 and \<256 as a result of early response, past infection or non-specific reactivity (IgM). In both groups, serological interpretation was complicated as in most cases the convalescent serum was lacking.

###### 

Study 1 (retrospective). Results of serology and PCR for the *Rickettsia* spp and *Borrelia* spp. in sera S1--S3

  No.               Age/sex   Duration of symptoms (days)   S1     S2     Weeks/S1--S2   S3     Months/ S1--S3   PCR/CSF   Borrelia IgG/IgM   Treatment   Tick bite                   
  ----------------- --------- ----------------------------- ------ ------ -------------- ------ ---------------- --------- ------------------ ----------- ----------- ------- ------- ----
  Facial palsy                                                                                                                                                                        
   R1               70/F      2                             \<64   64     \<64           64     1.5              \<64      \<64               10          NA          neg     P, AV   ND
   R2               53/M      40                            64     128    NA             NA                      NA        NA                             NA          neg     LT      ND
   R3               72/F      3                             64     64     NA             NA                      \<64      \<64               10          NA          neg     P       N
   R4               64/M      14                            64     512    NA             NA                      NA        NA                             NA          neg     LT      ND
   R5               70/F      7                             \<64   64     NA             NA                      NA        NA                             NA          neg     LT      ND
   R6               24/M      7                             \<64   256    NA             NA                      NA        NA                             neg         neg     P       N
   R7               25/M      7                             64     512    NA             NA                      NA        NA                             NA          neg     P       ND
   R8               16/F      9                             \<64   256    NA             NA                      NA        NA                             neg         neg     LT      N
   R9               23/F      3                             64     128    NA             NA                      \<64      \<64               11          NA          neg     LT      ND
   R10              12/F      3                             64     64     NA             NA                      NA        NA                             NA          neg     LT      Y
   R11              25/M      5                             \<64   256    128            1024   4                64        128                10          pos         G−/M+   AV      N
   R12              51/M      2                             \<64   128    NA             NA                      NA        NA                             pos         neg     AV      ND
   R13              37/F      5                             \<64   256    64             64     5                NA        NA                             NA          neg     P       N
   R14              39/F      25                            64     512    NA             NA                      NA        NA                             NA          neg     P       ND
   R15              60/M      12                            512    128    NA             NA                      NA        NA                             NA          neg     DC      Y
   R16              47/F      4                             64     1024   NA             NA                      NA        NA                             NA          neg     DC, P   ND
   R17              38/M      6                             64     128    NA             NA                      NA        NA                             NA          neg     DC      Y
   R18              49/M      2                             \<64   64     128            \<64   10               NA        NA                             NA          neg     P       ND
   R19              25/F      4                             \<64   256    NA             NA                      NA        NA                             NA          neg     LT      N
   R20              76/M      3                             \<64   128    NA             NA                      NA        NA                             NA          neg     LT      ND
   R21              28/F      4                             \<64   256    128            512    7                64        128                4           NA          neg     LT,P    N
   R22              69/M      4                             \<64   128    NA             NA                      NA        NA                             NA          neg     LT      ND
   R23              14/M      7                             64     512    NA             NA                      NA        NA                             NA          neg     LT      ND
   R24              6/M       4                             64     128    NA             NA                      NA        NA                             NA          neg     LT      ND
  Sudden deafness                                                                                                                                                                     
   R25              60/M      90                            512    \<64   NA             NA                      NA        NA                             NA          neg     P       ND
   R26              67/F      2                             \<64   64     64             \<64   4                NA        NA                             NA          neg     P       ND
   R27              65/F      53                            1024   64     NA             NA                      NA        NA                             NA          neg     LT      ND
   R28              55/F      4                             64     \<32   NA             NA                      NA        NA                             NA          neg     P       ND
   R29              77/F      3                             \<64   256    NA             NA                      NA        NA                             NA          neg     P       ND
   R30              72/M      3                             \<64   128    NA             NA                      NA        NA                             NA          neg     LT      ND
   R31              82/F      5                             \<64   512    NA             NA                      NA        NA                             NA          neg     P,AV    ND
   R32              76/M      3                             \<64   64     NA             NA                      64        128                4           NA          neg     LT      ND
   R33              51/M      7                             128    128    NA             NA                      NA        NA                             NA          neg     LT      ND
   R34              59/M      2                             \<64   128    NA             NA                      NA        NA                             NA          neg     P       ND
   R35              46/F      12                            \<64   256    NA             NA                      NA        NA                             NA          neg     P       ND
   R36              60/F      2                             \<64   128    NA             NA                      NA        NA                             NA          neg     P       ND
   R37              27/F      9                             \<64   128    NA             NA                      NA        NA                             NA          neg     P       Y
   R38              71/F      7                             64     128    NA             NA                      NA        NA                             NA          neg     P       ND
   R39              12 M      2                             \<64   128    NA             NA                      NA        NA                             pos         neg     P       ND
   R40              52/F      10                            64     64     NA             NA                      NA        NA                             NA          neg     P       ND
   R41              31/M      1                             \<64   \<64   NA             NA                      64        \<32               12          NA          neg     P       ND
   R42              54/M      4                             64     512    NA             NA                      NA        NA                             NA          neg     P       ND
   R43              42/F      4                             \<64   512    64             1028   4                NA        NA                             NA          neg     P,AV    N
   R44              65/M      6                             \<64   256    NA             NA                      NA        NA                             NA          neg     P       N

CSF, cerebrospinal fluid; NA, not applicable; AV, antiviral; DC, doxycycline; neg, negative; pos, positive; P, penicillin; LT, local treatment; ND, no data; N, no; Y, yes; R1--R44, retrospective patient number 1 to 44.

For three (R11, R12 and R39) of the six patients analysed using PCR, the CSF sample was positive in real-time PCR and also produced amplicons, in conventional PCR, of partial regions of the 17 kDa protein gene. The obtained, chosen complete sequences for these three patients were 394, 386 and 394 bp (17 kDa), respectively, and analyses of these amplicons shared 100% similarity with the corresponding gene sequence of *R. felis* (GenBank accession number CP000053.1). Due to the limited availability of extracted DNA no amplicons good enough for sequencing in the assays of the *omp*B and *omp*A genes were obtained. No attempt was made to detect DNA in blood or serum samples.

Only one (R11) of 70 patients was seroreactive (IgM) for *Borrelia* spp. as well. The laboratory results of all patients in Study 1 are summarized in Table[1](#tbl1){ref-type="table"}, and the symptoms and the laboratory results of the three PCR-positive patients are summarized in Table[2](#tbl2){ref-type="table"}.

###### 

Summary of the laboratory findings for the PCR-positive patients in Study 1

  Characteristics                 R11        R12              R39
  ------------------------------- ---------- ---------------- ----------------
  Sex, age in years               F, 25      M, 51            M, 12
  Previous diseases               None       None             None
  Month                           Oct        Feb              Aug
  Duration of symptoms/days       5          10               3
  Duration of facial palsy/days   3          8                NA
  Duration of hearing loss/days   NA         NA               5
  Fever (°C)                      37.4       35.5             36.8
  Headache                        Yes        Yes              No
  Dizziness                       No         No               No
  Stiff neck/neck pains           No/No      No/Yes           No
  Photophobia                     No         No               No
  Body-aches, pains               No         Yes              No
  Rash                            No         No               No
  Treatment (days)                                            
   AV                             10         NA               NA
   DC                             NA         10 (0.2 g/day)   10 (0.2 g/day)
   P                              7          NA               60
  C-reactive protein (mg/l)       \<5        \<8              9
  WBC count (g/l)                 6.3        5.3              7.7
  CSF results                                                 
   CSF cells total                \<2        3                13
   Mono                           0          3                13
   Albumin (mg/l)                 Normal     Normal           Normal
   Blood glucose ratio            Normal     Normal           Normal
  PCR results                                                 
   Real-time PCR                                              
    *glt*A                        pos        pos (2)          pos (2)
   PCR+seq-id                                                 
    *omp*B                        neg        ND               ND
    *omp*A                        ND         ND               neg
    17 kDa                        R.f        R.f (2)          R.f (2)
    *glt*A                        ND         neg              ND
  Serology                                                    
   Acute phase/s                                              
    Ric-MIF IgG                   \<64       \<64             \<64
    Ric-MIF IgM                   256        128              128
   Convalescent phase/s                                       
    Ric-MIF IgG                   128        NA               NA
    Ric-MIF IgM                   1024       NA               NA
   Borrelia (IU/ml)                                           
    Serum                         neg        neg              neg
    (Index) CSF                   neg        neg              neg
   TBE serology                   ND         neg              ND
   Herpes serology                neg        neg              neg
   Serology enterovirus           neg        ND               ND
  Brain CT                        Normal     ND               Normal
  Outcome                         Restored   Restored         Restored

AV, antiviral; DC, doxycycline; WBC, white blood cell; CSF, cerebrospinal fluid; P, penicillin; PCR, polymerase chain reaction; Ric, rickettsia; seq-id, sequence identity; TBE, tick borne encephalitis; R.f, *R. felis*; ND, not done; NA, not applicable; pos, positive; neg, negative; MIF, microimmunofluorescence.

Study 2 (prospective)
---------------------

The laboratory results of the consecutive patients are summarized in Table[3](#tbl3){ref-type="table"}. Two (P2, P14) of 20 patients with facial palsy and 8/37 patients (P22, P23, P28, P29, P30, P33, P38, P44) with SD presented a fourfold rise in IgG antibody titres judged as confirmative of infection. However, concerning P22 and P23, on the grounds that 23 (P22) and 20 (P23) weeks had passed between S1 and S2, it was assumed that the antibody levels peaked already 3--4 months earlier and were in fact on the way down in the latter assay (S2). Two of the patients (P12, P15) with FNP had serological findings with IgG titres ≥256 indicating a recent or current infection and judged as probable cases and one of the patients with SD (P41) showed a twofold rise in IgG titre and a fourfold rise in IgM titre suggestive of infection. Four of 20 and eight of 37, respectively, were seronegative to *Rickettsia* spp., whilst 12/20 and 20/37, respectively, were seroreactive with IgG and/or IgM antibodies equal to or higher than the cut-off dilution of 1:64. About half of the seroreactive patients only had IgM between 1:64 and 1:128 and were non-reactive for IgG, perhaps as a result of non-specific cross-reactivity due to exposure to other organisms, autoimmune responses or possibly as a sign of a previous exposure. Of all the 57 patients analysed for acute and convalescent sera only one (P25) had IgG antibodies against *Borrelia* spp. Other symptoms such as fever and/or headache occurred, but skin manifestations or swollen lymph nodes were not seen.

###### 

Study 2 (prospective) results of serology for paired sera (S1, S2) for the *Rickettsia* spp. seroreactive patients and for *Borrelia* spp.

  No.               Age/ sex   Duration of symptoms (days)   S1     S2     Weeks/S1--S2   Borrelias IgG/IgM (S1/S2)   Treatment   Tick bite           
  ----------------- ---------- ----------------------------- ------ ------ -------------- --------------------------- ----------- ----------- ------- ----
  Facial palsy                                                                                                                                        
   P1               51/F       24                            \<64   512    64             256                         20          neg/neg     P       ND
   P2               53/F       6                             64     128    256            64                          6           neg/neg     P, DC   ND
   P3               47/M       4                             \<64   \<64   64             \<64                        20          ND/neg      P       ND
   P4               68/F       3                             \<64   \<64   64             \<64                        5           neg/neg     LT      ND
   P5               55/F       5                             64     128    NA             NA                                      neg/neg     P, AV   N
   P6               57/F       4                             \<64   64     \<64           \<64                        4           neg/neg     P       ND
   P7               78/F       3                             \<64   64     \<64           \<64                        7           neg/neg     LT      ND
   P8               23/F       5                             64     512    64             256                         4           neg/neg     P, DC   ND
   P9               55/F       3                             \<64   256    \<64           256                         3           neg/neg     LT      ND
   P10              30/F       4                             64     256    NA             NA                                      ND/neg      P       ND
   P11              60/F       5                             64     256    \<64           128                         4           neg/neg     DC      ND
   P12              35/F       5                             256    512    256            256                         6           ND/neg      P, DC   ND
   P13              46/F       3                             \<64   \<64   \<64           128                         7           ND/neg      P       ND
   P14              39/M       3                             \<64   64     128            256                         5           ND/neg      DC      ND
   P15              47/M       16                            256    \<64   128            64                          5           neg/neg     P       ND
   P16              19/M       3                             \<64   128    NA             NA                                      ND/neg      P       ND
  Sudden deafness                                                                                                                                     
   P17              65/F       4                             \<64   128    64             128                         3           neg/neg     P, DC   ND
   P18              66/F       5                             \<64   512    64             128                         4           neg/neg     DC      ND
   P19              57/M       3                             \<64   \<64   64             \<64                        4           neg/neg     P       ND
   P20              47/M       4                             \<64   128    \<64           128                         22          neg/neg     P       ND
   P21              41/F       4                             \<64   128    NA             NA                                      neg/neg             ND
   P22              52/M       3                             \<64   \<64   256            128                         23          neg/neg     P, AV   ND
   P23              72/M       2                             \<64   256    512            512                         20          ND/neg      P,      ND
   P24              52/M       6                             \<64   128    NA             NA                                      neg/neg     P, AV   ND
   P25              74/F       8                             \<64   256    NA             NA                                      G+/M−/neg           ND
   P26              37/M       2                             \<64   128    \<64           64                          7           neg/neg     DC      ND
   P27              35/M       1                             \<64   256    64             64                          9           ND/neg              ND
   P28              72/M       2                             \<64   256    128            128                         5           neg/neg     P, DC   ND
   P29              52/M       16                            64     64     256            \<64                        9           neg/neg     P       ND
   P30              63/M       3                             \<64   256    128            128                         10          neg/neg     P, DC   ND
   P31              31/M       6                             \<64   64     \<64           \<64                        4           neg/neg     P       ND
   P32              70/M       3                             \<64   \<64   64             \<64                        5           neg/neg             ND
   P33              69/M       4                             \<64   \<64   128            128                         5           neg/neg     P       ND
   P34              46/M       2                             \<64   \<64   64             64                          24          neg/neg     P, AV   ND
   P35              51/M       320                           \<64   \<64   \<64           128                         10          neg/neg     P       ND
   P36              68/F       6                             \<64   \<64   64             \<64                        5           neg/neg             ND
   P37              81/M       25                            \<64   128    \<64           128                         4           neg(S2)             ND
   P38              82/F       8                             \<64   \<64   128            128                         9           neg/neg     P, DC   ND
   P39              74/M       6                             \<64   \<64   64             64                          5           neg/neg     AV      ND
   P40              43/F       4                             \<64   \<64   \<64           128                         12          neg/neg     P       ND
   P41              68/M       4                             64     \<64   128            256                         7           neg/neg             ND
   P42              63/F       3                             64     128    64             128                         4           neg/neg             ND
   P43              45/F       4                             \<64   \<64   \<64           256                         6           neg/neg     P       ND
   P44              71/M       5                             \<64   \<64   512            512                         11          neg/neg     P       ND
   P45              57/M       3                             \<64   \<64   \<64           256                         11          neg/neg     P, AV   ND

ND, not done; P1--P45, prospective patient number 1 to 45. P, penicillin; DC, doxycycline; LT, local treatment; AV, antiviral; neg, negative.

Western blot for patients P12, P23, P29 and P44 showed a specific response in the 120--150 kDa region for IgG to whole-cell antigen of *R. helvetica* (Fig. [1](#fig01){ref-type="fig"}). Absorption with *R. helvetica* antigen reduced the dilutions in IFA for serum P23 from 1:512 to \<1:64, and the end-point dilutions for detection in WB with whole-cell antigen was reduced from 1:1600 to \<1:400 (Fig. [1](#fig01){ref-type="fig"}). Negative controls in the form of serum from healthy blood donors showed no specific reactions.

![Western blot analysis of IgG antibodies against *Rickettsia helvetica* whole-cell antigen. Lane A demonstrates specific proteins and the lipopolysaccharide (LPS) ladders reacting with a polyclonal rabbit antiserum. Lanes B--E demonstrate the specific reactions against *R. helvetica* proteins in the 110--150 kDa region for serum P29 = (B), P12 = (C), P44 = (D) and P23 = (E) in dilutions 1:500. In lanes F--H step-by-step weaker specific reactions to both protein and LPS antigens are shown in dilutions 1:600 (F) and 1:1200 (G) for serum P23 until the reaction has vanished in dilution 1:2400 (H). Lanes I and J demonstrate serum P23 in dilutions 1:600 and 1:1200, respectively, where the antigen−antibody reaction was eliminated after previous absorption with *R. helvetica* whole-cell antigen.](ene0021-0206-f1){#fig01}

Discussion
==========

The present study shows that between 10% and 20% (CI 3.3--44.3) of patients with peripheral facial palsy (Bell\'s palsy) and between 9.9% and 24.3% (CI 2.6--41.6) of patients with SD presented serological and/or molecular evidence of an underlying rickettsial infection as the cause of cranial neuritis. In four cases the serological specificity was demonstrated by WB, and in three other patients rickettsial DNA was detected in the CSF, where sequencing and analyses of the obtained amplicons showed 100% similarity with the deposited sequence of *R. felis*. Moreover, our study shows that neither FNP nor SD, in any of the cases where CSF was available, was associated with neuroborreliosis and that only two of the 127 patients had antibodies to *Borrelia* spp.

The cause of peripheral facial palsy is unknown in 70% of cases. FNP as an isolated cranial neuropathy has been reported to occur during LB or to accompany acute lymphocytic meningitis and, in some studies, has been demonstrated to account for as much as 65% of acute facial palsy during childhood [@b25],[@b26]. In previous studies, a Lyme infection has been diagnosed in approximately 10%--20% of patients in Sweden with facial palsy [@b27] and 10% of adults in Norway [@b28]. A lower rate of FNP associated with meningitis has been observed during winter indicating that, in these cases, FNP may be caused by other agents [@b29]. In the rickettsial-DNA-positive patients in Study 1, a slight pleocytosis (0--13 mononuclear cells/l) was found in the CSF, with otherwise normal laboratory values. None of these patients were co-infected with LB. In both Study 1 and Study 2 there was a relatively even distribution of onset of illness in the summer or winter months amongst patients, and of the PCR-positive patients all had become ill between August and February.

There have been only a few reports of isolated facial nerve palsies caused by SFR, in these cases with *R. conorii* as the agent [@b3],[@b10]. In one case *R. felis* was reported to cause bilateral hearing loss and in two other cases photophobia and signs of meningismus were found [@b30]. These previously reported patients exhibited low white blood cell counts in the blood and CSF, and a serologically confirmed Epstein--Barr virus infection was found in one of them. These laboratory findings are in good accordance with the findings from previously reported cases of *R. helvetica* or *R*. *felis* meningitis, where co-infection with herpes simplex virus type 2 was present in one case [@b16],[@b17]. It is probable, in those cases, that the co-infection may have reactivated the Epstein--Barr virus infection or herpes simplex virus type 2 infection, but the opposite is conceivable, as is simultaneous infection by both agents. The low white blood cell counts make it difficult to use these values to exclude a rickettsial infection, and the assessment will therefore be dependent on other methods such as serology or PCR. Besides those patients who showed fourfold seroconversion or a significant rise in IgG titre -- indicating recent, current or probable infection -- a number of patients had IgG titres below the cut-off but presented significant increases in titres of IgM antibodies against *Rickettsia* spp., where the highest observed titre was 1/512. The serological IgM response is likely to be specific when the increase in titre is higher than or equal to 256, but the significance of this response, as well as the question of why IgG antibodies did not develop after some weeks, has to be studied further. Three out of three PCR-positive patients showed only IgM antibodies in the acute serum sample. The difficulty in the acute assessment is to know which of these patients have true infections and which of them have non-specific IgM reactivity. In some of the cases the IgM reactivity was tested positive in WB with whole-cell antigen suggesting that the IgM response sometimes may be specific. It is possible, with the reservation that only six CSF samples were available in the study, that the combination of serology with PCR of CSF in the early stages may provide better guidance as to the causative agents.

Thus far, only one case of African tick bite fever has been reported that was complicated by subacute neuropathy of the eighth cranial nerve [@b31]. Direct rickettsial invasion of the nervous system has been described in patients with acute neurological complications, but subacute involvement of rickettsiosis is believed to be secondary to immune-mediated mechanisms caused by widespread endothelial inflammation and progression to a vasculitic process that may affect any organ [@b32],[@b33].

Patients with neuroborreliosis and facial palsy are usually treated with antibiotics, whilst ambiguous facial palsies without neuroborreliosis are given a high dose of cortisone in the acute phase. Three patients in the retrospective group and 14 patients in the prospective group received antibiotics. The antibiotic treatment was in some cases a result of a primary suspicion of borreliosis which later could not be confirmed. In the prospective group most of the patients who showed high titres against rickettsia or seroconversion were treated with tablet doxycycline (100 mg orally twice a day), continued for 10 days (Tables[1](#tbl1){ref-type="table"} and [3](#tbl3){ref-type="table"}). In previously documented patients, it has been found that the rickettsial disease might be relatively mild [@b14]. Treatment with cortisone suppresses the symptoms of inflammation and swelling, but it is reasonable to assume that specific antibiotic treatment and antibiotic protection during cortisone treatment should also be given in cases where a rickettsial infection is judged to have caused the paralysis. Doxycycline is preferred over other tetracyclines for treatment of rickettsial infections, and 10 days of treatment is typical. However, the newer macrolides and fluoroquinolones may also be of interest as a form of therapy [@b34],[@b35]. Generally, prompt initiation of anti-rickettsial therapy is important and may result in a better outcome. These issues must be studied further, together with studies aimed at elucidating the ecology and epidemiology and determining the actual incidence of *Rickettsia* spp. infection in humans as well as its common clinical signs and symptoms.
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